STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMUX
  4. [Form 4] Immunic, Inc. Insider Trading Activity

[Form 4] Immunic, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Insider Tardio Jason
Role President and COO
Type Security Shares Price Value
Grant/Award Stock Appreciation Right 330,000 $0.00 --
Grant/Award Stock Appreciation Right 660,000 $0.00 --
Grant/Award Stock Appreciation Right 660,000 $0.00 --
Grant/Award Stock Appreciation Right 330,000 $0.00 --
Grant/Award Stock Appreciation Right 330,000 $0.00 --
Holdings After Transaction: Stock Appreciation Right — 330,000 shares (Direct)
Footnotes (1)
  1. The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock. Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof. Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof. Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering"). Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Tardio Jason
(Last) (First) (Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200
(Street)
NEW YORK NY 10036
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Right $0.77 07/16/2025 A 330,000 08/01/2026 07/16/2035 Common Stock(1) 330,000 $0.00 330,000 D
Stock Appreciation Right $0.77 07/16/2025 A 660,000 08/01/2026(2) 07/16/2035 Common Stock(1) 660,000 $0.00 660,000 D
Stock Appreciation Right $0.77 07/16/2025 A 660,000 08/01/2026(3) 07/16/2035 Common Stock(1) 660,000 $0.00 660,000 D
Stock Appreciation Right $0.77 07/16/2025 A 330,000 08/01/2026(4) 07/16/2035 Common Stock(1) 330,000 $0.00 330,000 D
Stock Appreciation Right $0.77 07/16/2025 A 330,000 08/01/2026(5) 07/16/2035 Common Stock(1) 330,000 $0.00 330,000 D
Explanation of Responses:
1. The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.
2. Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof.
3. Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof.
4. Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering").
5. Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.
/s/ Jason Tardio 07/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR